Eli Lilly & Co. vs Merck & Co., Inc.
LLY vs MRK — side-by-side comparison from reported financials. LLY leads 8, MRK leads 3 of 11 comparable metrics.
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
Merck & Co., Inc.
MRK · Healthcare
$146.33+2.77%Mixed
| Metric | LLY | MRK |
|---|---|---|
| Price | $1 177.20 | $146.33 |
| Market cap | $1.05T | $361B |
| Revenue (TTM) | $79.7B | $66.6B |
| Revenue growth | +31.7% | +3.1% |
| Net margin | 33.5% | 4.8% |
| Free cash flow | $18.2B | $16.1B |
| Net cash (debt) | ($35.2B) | ($34.8B) |
| 1-year price return | +37.6% | +67.2% |
| P/E | 41.6 | 113.2 |
| P/E vs own history (cheap-side %) | 88% | 7% |
| Dividend yield | 0.52% | 2.31% |
| Return on equity | 93% | 7% |
| Altman Z-score | 7.10 | — |
| CV checks passed | 11 of 11 | 9 of 11 |
| Employees | 50,000 | 75,000 |
Full résumé-style profiles: LLY CV · MRK CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.